RNS
SkinBioTherapeutics PLC

SkinBioTherapeutics - Holding(s) in Company

RNS Number : 5569N
SkinBioTherapeutics PLC
01 February 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SkinBioTherapeutics plc

 

Company No: 09632164 (England)

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Seneca Partners Limited

City and country of registered office (if applicable)

Haydock, Greater Manchester UK

4. Full name of shareholder(s) (if different from 3.)v

Name

Share Nominees Limited, WCS Nominees Limited, Platform Securities Nominees Limited.

City and country of registered office (if applicable)

Aylesbury, Bucks, UK, London UK

5. Date on which the threshold was crossed or reachedvi:

29/01/2021

6. Date on which issuer notified (DD/MM/YYYY):

01/02/2021

7. Total positions of person(s) subject to the notification obligation


Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

12.9


12.9

155,889,922

 

Position of previous notification (if

applicable)

13.5


13.5


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary Shares

GB00BF33H870

        

 20,110,387

 

N/A

12.9

N/A











SUBTOTAL 8. A


B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights


















SUBTOTAL 8. B 1




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights






















SUBTOTAL 8.B.2



 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

 

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 





 





 





 





 





 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder


 

The number and % of voting rights held


 

The date until which the voting rights will be held


 


 

11. Additional informationxvi

 


 

 

 

Place of completion

Haydock, Greater Manchester UK

Date of completion

1 February 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLTBMBTMTBMBPB
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience.